Rheumatoid arthritis

Plasma levels of multiple cardiovascular- and inflammation-related proteins analysed for associations with disease activity and anti-cyclic citrullinated peptide status in active early rheumatoid arthritis

Clin Exp RheumatolPublished Cross-sectional study

Authors' conclusion

In active and early RA, the findings regarding CHIT1, SHPS-1 TIMP-4, IL2-RA, E-selectin, and CCL16 differed between the two anti-CCP groups. In addition, we identified two patient clusters that were independent of the anti-CCP status.

Study context

Population
Early, treatment-naive, highly inflamed rheumatoid arthritis (RA) patients from the OPERA trial
Participants
180 participants
Exposure
Anti-CCP-negative vs anti-CCP-positive early RA
  • Anti-CCP-negativen = 63
  • Anti-CCP-positiven = 117reference
Outcome
Plasma levels of 92 cardiovascular- and inflammation-related proteins (Olink CVD-III panel) and their correlation with RA disease activity, by anti-CCP status
Methodological detailshierarchical cluster analysis
  • Hierarchical cluster analysis

Main finding

As reported in the abstract

CIRP plasma levels by anti-CCP status
  • CHIT1 and SHPS-1 increased and TIMP-4 decreased in anti-CCP-negative vs anti-CCP-positive
  • Strongest associations with disease activity: IL2-RA and E-selectin in anti-CCP-negative; CCL16 in anti-CCP-positive
  • None of the differences passed the Hochberg sequential multiplicity test; Cardiovascular- and inflammation-related proteins (CIRPs) were interacting, so the procedure's prerequisites were not fulfilled

Observational data: associations, not effects.

Further findings

CIRP level-based cluster analysis

Two patient clusters identified in both anti-CCP groups; demographic and clinical characteristics similar in the two clusters for each anti-CCP group

Original publication

Plasma levels of multiple cardiovascular- and inflammation-related proteins analysed for associations with disease activity and anti-cyclic citrullinated peptide status in active early rheumatoid arthritis. Clin Exp Rheumatol. Published 1 October 2022. doi:10.55563/clinexprheumatol/hrjqdm

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.